Altimmune Inc
ALT3.860USD
-0.120-3.02%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
369.01MMarket Cap
LossP/E TTM
More Details of Altimmune Inc Company
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Altimmune Inc Info
Ticker SymbolALT
Company nameAltimmune Inc
IPO dateOct 06, 2005
CEODurso (Jerome Benedict)
Number of employees59
Security typeOrdinary Share
Fiscal year-endOct 06
Address910 Clopper Road
CityGAITHERSBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20878-1361
Phone12406541450
Websitehttps://altimmune.com/
Ticker SymbolALT
IPO dateOct 06, 2005
CEODurso (Jerome Benedict)
Company Executives of Altimmune Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
Director
Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
23.08K
+130.78%
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Ms. Linda M. Richardson
Ms. Linda M. Richardson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
Director
Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
23.08K
+130.78%
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.56%
State Street Investment Management (US)
3.45%
Two Sigma Investments, LP
3.30%
Tang Capital Management, LLC
2.04%
Other
79.53%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.56%
State Street Investment Management (US)
3.45%
Two Sigma Investments, LP
3.30%
Tang Capital Management, LLC
2.04%
Other
79.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.59%
Hedge Fund
9.67%
Investment Advisor/Hedge Fund
8.98%
Research Firm
2.85%
Individual Investor
0.65%
Bank and Trust
0.36%
Insurance Company
0.03%
Pension Fund
0.03%
Other
58.85%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
397
42.20M
45.25%
+62.13K
2025Q3
414
42.28M
51.76%
+3.92M
2025Q2
414
38.35M
59.50%
-499.87K
2025Q1
418
38.87M
69.79%
-15.45M
2024Q4
424
41.24M
78.28%
+1.10M
2024Q3
424
40.14M
86.96%
-2.89M
2024Q2
422
42.99M
89.21%
-1.89M
2024Q1
404
45.12M
79.71%
-11.40M
2023Q4
374
33.97M
69.19%
+3.12M
2023Q3
355
30.89M
106.90%
-4.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.17M
5.85%
+772.36K
+17.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.75M
6.52%
+223.90K
+4.05%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.12%
-637.93K
-18.81%
Jun 30, 2025
Two Sigma Investments, LP
584.60K
0.66%
-827.52K
-58.60%
Jun 30, 2025
Tang Capital Management, LLC
2.75M
3.12%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.19%
+229.00K
+13.42%
Jun 30, 2025
Susquehanna International Group, LLP
1.62M
1.84%
+543.68K
+50.53%
Jun 30, 2025
Citadel Advisors LLC
523.46K
0.59%
+523.46K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
533.42K
0.6%
+194.01K
+57.16%
Jun 30, 2025
Knoll Capital Management, LLC
1.12M
1.27%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.57%
Virtus LifeSci Biotech Clinical Trials ETF
0.38%
State Street SPDR S&P Biotech ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.09%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.57%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.38%
State Street SPDR S&P Biotech ETF
Proportion0.15%
Fidelity Enhanced Small Cap ETF
Proportion0.09%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Altimmune Inc?
The top five shareholders of Altimmune Inc are:
The Vanguard Group, Inc. holds 5.17M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.75M shares, accounting for 6.52% of the total shares.
State Street Investment Management (US) holds 2.75M shares, accounting for 3.12% of the total shares.
Two Sigma Investments, LP holds 584.60K shares, accounting for 0.66% of the total shares.
Tang Capital Management, LLC holds 2.75M shares, accounting for 3.12% of the total shares.
The Vanguard Group, Inc. holds 5.17M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.75M shares, accounting for 6.52% of the total shares.
State Street Investment Management (US) holds 2.75M shares, accounting for 3.12% of the total shares.
Two Sigma Investments, LP holds 584.60K shares, accounting for 0.66% of the total shares.
Tang Capital Management, LLC holds 2.75M shares, accounting for 3.12% of the total shares.
What are the top three shareholder types of Altimmune Inc?
The top three shareholder types of Altimmune Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Altimmune Inc (ALT)?
As of 2025Q4, 397 institutions hold shares of Altimmune Inc, with a combined market value of approximately 42.20M, accounting for 45.25% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.52%.
What is the biggest source of revenue for Altimmune Inc?
In --, the -- business generated the highest revenue for Altimmune Inc, amounting to -- and accounting for --% of total revenue.
